Trump's new health chief makes UK's biggest pharma companies nervous

Most of Wall Street feels good about Donald Trumps win‚ but pharma companies dont share the excitement. The reason: his pick for health secretary Robert F Kennedy Jr – a choice thats making drug makers very un-comfortable

For too long Americans have been crushed by the industrial food complex and drug companies who have engaged in deception and disinformation

Last year Kennedy made news with some eye-catching statements about covid-19 vaccines (which he called the most dangerous ever made) and shared other non-standard views about medicine. His ideas about removing food additives and water system changes made pharma stocks drop fast – Moderna Pfizer and others lost value right after the announcement

UKʼs biggest medicine makers are now in a tough spot. The math isnt good for companies like AstraZeneca and GSK‚ who get almost half their money from US sales. These science-based businesses – which are super-important for Britainʼs economy – might face real problems in their number-one market

The industry needs to act quick-like. Hereʼs what experts say needs to happen:

• Get better at explaining to people why their work matters
• Push hard with government contacts
• Make sure regular Americans understand whats at stake
• Keep trade routes open between UK-US

Some think Kennedy might be less extreme once heʼs actually doing the job – kinda like what happened in Trumps first time as president. But his long-time anti-pharma ideas make people think he wont change his mind easy

The next few months will be super-important as Kennedy builds his team and gets ready to take over. British drug makers need to prepare for a bumpy ride in the US market‚ and theyʼll need UK government help to keep things running smooth